A paediatric case of successful non-myeloablative bone marrow transplantation after azacitidine therapy for non-Down syndrome acute megakaryoblastic leukaemia with monosomy 7
Corresponding Author
Yuhki Koga
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Yuhki Koga, Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Tel.: +81 92 642 5093
Fax: +81 92 642 5100
E-mail: [email protected]
Search for more papers by this authorUtako Oba
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorWakako Kato
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorHiroaki Ono
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorKentaro Nakashima
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorHidetoshi Takada
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorCorresponding Author
Yuhki Koga
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Yuhki Koga, Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Tel.: +81 92 642 5093
Fax: +81 92 642 5100
E-mail: [email protected]
Search for more papers by this authorUtako Oba
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorWakako Kato
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorHiroaki Ono
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorKentaro Nakashima
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorHidetoshi Takada
Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
Search for more papers by this authorAbstract
We report a patient with non-Down syndrome AML, also known as AMKL, with monosomy 7, who was also obese and had a hearing impairment and mental retardation. Non-myeloablative bone marrow transplantation was performed successfully after the patient received less aggressive azacitidine treatment, without the usual intensive induction chemotherapy regimen for AML.
References
- 1Inaba H, Zhou Y, Abla O, et al. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: A retrospective international study. Blood 2015: 126: 1575–1584.
- 2Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: A single institution's experience. Blood 2001: 97: 3727–3732.
- 3Barnard DR, Alonzo TA, Gerbing RB, et al. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group. Pediatr Blood Cancer 2007: 49: 17–22.
- 4Manola KN, Panitsas F, Polychronopoulou S, et al. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: Correlations with clinical characteristics and outcome. Cancer Genet 2013: 206: 63–72.
- 5Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomized, open-label, phase III study. Lancet Oncol 2009: 10: 223–232.
- 6Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with 30% blasts. Blood 2015: 126: 291–299.
- 7Furlan I, Batz C, Flotho C, et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood 2009: 113: 2867–2868.
- 8Cseh A, Niemeyer CM, Yoshimi A, et al. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: A retrospective analysis of the EWOG-MDS study group. Blood 2015: 125: 2311–2313.
- 9Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970: 30: 2760–2769.
- 10Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010: 5: e9001.
- 11Khan R, Aggerholm A, Hokland P, Hassan M, Hellström-Lindberg E. A pharmacodynamic study of 5-azacytidine in the P39 cell line. Exp Hematol 2006: 34: 35–43.
- 12Hofmann WK, Takeuchi S, Takeuchi N, Thiel E, Hoelzer D, Koeffler HP. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. Leuk Res 2006: 30: 1347–1353.
- 13Wang J, Yi Z, Li Z. The effect of decitabine on megakaryocyte maturation and platelet release. Thromb Haemost 2011: 106: 337–343.
- 14Cong L, Guangsheun H, Song J, et al. A patient with acute megakaryoblastic leukaemia who achieved CRi after decitabine treatment. Leuk Res 2012: 36: e168–e170.
- 15Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012: 18: 1211–1218.
Citing Literature
